Loss of p53 Expression in Myc-induced B Lineage Tumors

  • R. H. Scheuermann
  • S. R. Bauer
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 182)


Transgenic mice carrying an activated oncogene have been used extensively to investigate the mutational requirements for tumorigenesis. Transgenic mice carrying the c-myc gene under the control of the Immunoglobulin heavy chain enhancer express the transgene exclusively in lymphoid tissues (Adams et al 1985; Harris et al 1988; Schmidt et al 1988; Scheuermann and Bauer 1990). At an early age these mice develop normally with only small effects on the normal lymphoid compartments. Invariably the mice develop lymphoid tumors after a latent period of about 10 weeks. The tumors are clonal, that is they derive from a single precursor cell, as judged by the rearrangement status of the antigen receptor genes. The fact that the tumors which arise in these mice are clonal and develop after a certain latent period suggests that inappropriate expression of c-myc is not sufficient for tumorigenesis, and that additional events, probably mutational, are necessary for transformation. Thus, these transgenic mice provide an excellent model system for the identification of genes which collaborate with activated myc in lymphoid tumorigenesis.


Transgenic Mouse Lineage Tumor Endogenous mRNA Antigen Receptor Gene preB Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Adams JM, Harris AW, Pinkert CA, Corcoran M, Alexander WS, Cory S, Palmiter RD, Brinster RL (1985) The c-myc oncogene driven by Immunoglobulin enhancers induce lymphoid malignancy in transgenic mice. Nature 318, 533–538.PubMedCrossRefGoogle Scholar
  2. Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chlororform extraction. Anal. Biochem. 162, 156–159.PubMedCrossRefGoogle Scholar
  3. Giadano G, Ballerini P, Gong JZ, Inghirami G, Neri A, Newcomb EW, Magrath IT, knowles DM, Dalla-Favera R (1991) p53 mutations in human lymphoid malignancies: Association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. U.S.A. 88, 5413–5417.CrossRefGoogle Scholar
  4. Harris AW, Pinkeit CA, Crawford M, Langdon Y, Brinster RL, Adams JM (1988) The Eμmyc transgenic mouse: A model for high-incidence spontaneous lymphoma and leukemia of early B cells. J. Exp. Med. 167, 353–371.PubMedCrossRefGoogle Scholar
  5. Haupt Y, Alexander WS, Barri G, klinken SP, Adams JM (1991) Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in Eμ-myc transgenic mice. Cell 65, 753–763.PubMedCrossRefGoogle Scholar
  6. Langdon WY, Harris AW, Cory S (1989) Acceleration of B-lymphoid tumorigenesis in transgenic mice by v-Ha-ras and v-rafbni not v-abl. Oncogene Res. 4, 253–258.PubMedGoogle Scholar
  7. Levine AJ, Momand J, Finlay CA (1991) The p53 tumour suppressor gene. Nature 351, 453–456.PubMedCrossRefGoogle Scholar
  8. Orita M, Suzuki Y, Sekiya T, Hayashi K (1989) Rapid and sensitive detection of point mutations and DNA polymorphisms using the Polymerase chain reaction. Genomics 5, 874–879.PubMedCrossRefGoogle Scholar
  9. Prokocimer M, Shaklai M, BenBassat H, Wolf D, Goldfinger N, Rotter V (1986) Expression of p53 in human leukemias and lymphomas. Blood 68, 113–118.PubMedGoogle Scholar
  10. Saiki RK, Gelfand DH, Stoffel S, Scharf J, Higuchi R, Horn GT, Mullis KB, Erlich HA (1988) Primer-directed enzymatic amplification of DNA with a thermostable DNA Polymerase. Science 239, 487–494.PubMedCrossRefGoogle Scholar
  11. Scheuermann RH, Bauer SR (1990) Tumorigenesis in transgenic mice expressing the c-myc oncogene with various lymphoid enhancer elements. Curr. Topics Microbiol. Immunol. 166, 221–231.CrossRefGoogle Scholar
  12. Scheuermann RH, Bauer SR (1992) PCR-based mRNA quantification using an internal standard: A method for the analysis of oncogene expression. Methods Enzymol. in press.Google Scholar
  13. Schmidt EV, Pattengale PK, Weir L, Leder P (1988) Transgenic mice bearing the human c-myc gene activated by an immunoglobulin enhancer: A pre-B-cell lymphoma model. Proc. Natl. Acad. Sci. U.S.A. 85, 6047–6051.PubMedCrossRefGoogle Scholar
  14. van Lohuizen M, Verbeek S, Scheijen B, Wientjens E, van der Gulden H, Berns, A. (1991) Identification of cooperating oncogenes in Eμ-myc fransgenic mice by provirus tagging. Cell 65, 737–752.PubMedCrossRefGoogle Scholar
  15. Verbeek, S., van Lohuizen, M., van der Valk, M., Domen, J., kraal, G. and Bers, A. (1991) Mice bearing the Eμ-myc and Eμ-pim-1 transgenes develop pre-B-cell leukemia neonatally. Mol. Cell. Biol. 11, 1176–1179.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • R. H. Scheuermann
    • 1
    • 2
  • S. R. Bauer
    • 1
    • 2
  1. 1.Department of PathologyUniversity of Texas Southwestern Medical CenterDallasUSA
  2. 2.Laboratory of Molecular ImmunologyFDABethesdaUSA

Personalised recommendations